These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9175335)

  • 1. Rapid disease progression in two cases of myelodysplastic syndrome (MDS) following short therapy with G-CSF.
    Zomas A; Fisfis M; Stefanoudaki-Sofianatou K
    Haematologica; 1997; 82(2):253-4. PubMed ID: 9175335
    [No Abstract]   [Full Text] [Related]  

  • 2. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome.
    O'Malley DP; Whalen M; Banks PM
    Am J Hematol; 2003 Aug; 73(4):294-5. PubMed ID: 12879437
    [No Abstract]   [Full Text] [Related]  

  • 9. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.
    Rigolin GM; Porta MD; Ciccone M; Bugli AM; Bragotti LZ; Mauro E; Fraulini C; Rossi AR; Bardi A; Cuneo A; Castoldi G
    Br J Haematol; 2004 Aug; 126(4):501-7. PubMed ID: 15287942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes.
    Haematologica; 1999 Dec; 84(12):1057. PubMed ID: 10586204
    [No Abstract]   [Full Text] [Related]  

  • 12. [In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
    Takeyama H; Kajiguchi T; Miyata Y; Saito M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):873-8. PubMed ID: 10897214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca2+/calmodulin-dependent protein kinase IV.
    Mishima Y; Terui Y; Mishima Y; Katsuyama M; Mori M; Tomizuka H; Takizawa T; Miyazato A; Ueda M; Yamada M; Hayasawa H; Mizunuma N; Ishizaka Y; Ikeda K; Kato T; Ozawa K; Hatake K
    J Cell Physiol; 2002 May; 191(2):183-90. PubMed ID: 12064461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
    Bowen D; Hyslop A; Keenan N; Groves M; Culligan D; Johnson P; Shaw A; Geddes F; Evans P; Porter J; Cavill I
    Haematologica; 2006 May; 91(5):709-10. PubMed ID: 16670077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
    Yamada T; Tsurumi H; Hara T; Fukuno K; Goto H; Oyama M; Moriwaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):218-21. PubMed ID: 10774251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sweet syndrome associated with granulocyte colony-stimulating factor.
    Bidyasar S; Montoya M; Suleman K; Markowitz AB
    J Clin Oncol; 2008 Sep; 26(26):4355-6. PubMed ID: 18779624
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigation of coronary artery bypass grafting for a patient with myelodysplastic syndrome.
    Miyagi Y; Yamauchi S; Suzuki S; Kitagawa A; Masaki Y; Gomibuchi M; Tanaka S
    Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):250-3. PubMed ID: 11578269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group.
    Donadieu J; Leblanc T; Bader Meunier B; Barkaoui M; Fenneteau O; Bertrand Y; Maier-Redelsperger M; Micheau M; Stephan JL; Phillipe N; Bordigoni P; Babin-Boilletot A; Bensaid P; Manel AM; Vilmer E; Thuret I; Blanche S; Gluckman E; Fischer A; Mechinaud F; Joly B; Lamy T; Hermine O; Cassinat B; Bellanné-Chantelot C; Chomienne C;
    Haematologica; 2005 Jan; 90(1):45-53. PubMed ID: 15642668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.